
The Analyst
Pablo Zuanic, from Cantor Fitzgerald, kept Curaleaf among the firm’s top picks in the MSO group, with an Overweight rating and a price target at US$16.50.
The Thesis

The Analyst
Pablo Zuanic, from Cantor Fitzgerald, kept Curaleaf among the firm’s top picks in the MSO group, with an Overweight rating and a price target at US$16.50.
The Thesis